New Affinity Probe Targeting VEGF Receptors for Kinase Inhibitor Selectivity Profiling by Chemical Proteomics
journal contributionposted on 2014-05-02, 00:00 authored by Xin Ku, Stephanie Heinzlmeir, Dominic Helm, Guillaume Médard, Bernhard Kuster
Solid tumors are dependent for growth on nutrients and the supply of oxygen, which they often acquire via neoangiogenesis. Vascular endothelial growth factors and the corresponding receptors (VEGFRs) play central roles in this process, and consequently, the blockade of this pathway is one therapeutic strategy for cancer treatment. A number of small molecules inhibiting VEGFR inhibitors have been developed for clinical use, and a comprehensive view of target selectivity is important to assess the therapeutic as well as risk potential of a drug molecule. Recent advances in mass spectrometry-based chemical proteomics allow analyses of drug–target interactions under close-to-physiological conditions, and in this study, we report on the design, synthesis, and application of a small molecule affinity probe as a tool for the selectivity profiling of VEGFR and other kinase inhibitors. The probe is capable of binding >132 protein kinases, including angiokinases such as VEGFRs, PDGFRs, and c-KIT from lysates of cancer cell lines or human placenta tissue. Combining the new probe with Kinobeads in competitive binding assays, we were able to identify nanomolar off-targets of the VEGFR/PDGFR inhibitors pazopanib and axitinib. Because of its broad binding spectrum, the developed chemical tool can be generically used for the discovery of kinase inhibitor targets, which may contribute to a more comprehensive understanding of the mechanisms of action of such drugs.
kinase inhibitor targetstarget selectivityRecent advancesbinding assaysNew Affinity Probe Targeting VEGF Receptorschemical tooldrug moleculeKinase Inhibitor Selectivity Profilingcancer treatmentplacenta tissuegrowth factorsbinding spectrumkinase inhibitorsChemical ProteomicsSolid tumorscancer cell linesmolecule affinity probePDGFRVEGFR inhibitors